Tiziana Life Sciences Ltd (TLSA)
NASDAQ: TLSA · Real-Time Price · USD
1.545
-0.035 (-2.22%)
At close: May 11, 2026, 4:00 PM EDT
1.530
-0.015 (-0.97%)
After-hours: May 11, 2026, 4:10 PM EDT
Tiziana Life Sciences Employees
Tiziana Life Sciences had 9 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
9
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,047,889
Market Cap
197.18M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 9 | 0 | - |
| Dec 31, 2023 | 9 | 0 | - |
| Dec 31, 2022 | 9 | -5 | -35.71% |
| Dec 31, 2021 | 14 | 3 | 27.27% |
| Dec 31, 2020 | 11 | 3 | 37.50% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Karyopharm Therapeutics | 228 |
| Tonix Pharmaceuticals Holding | 142 |
| MediWound | 121 |
| Caribou Biosciences | 97 |
| Tenaya Therapeutics | 70 |
| Precision BioSciences | 68 |
| Corbus Pharmaceuticals Holdings | 36 |
TLSA News
- 25 days ago - Tiziana Life announces publication of preclinical data in bioRxiv preprint - TheFly
- 25 days ago - Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function - GlobeNewsWire
- 27 days ago - Tiziana Life Sciences Announces Late Breaking Poster Accepted for Presentation at the 7th World Parkinson Congress - GlobeNewsWire
- 5 weeks ago - Tiziana Announces Data Showing Nasal Anti-CD3 Improves Cognition Associated with Aging - GlobeNewsWire
- 2 months ago - Tiziana Life Sciences announces new data on nasal foralumab - TheFly
- 2 months ago - Tiziana Life Sciences Announces New Biomarker Data Showing Nasal Foralumab Downregulates CSF Inflammation, Upregulates Neuroprotective Pathways, and Correlates with Reduced Microglial Activation on PET Scans in na-SPMS Patients with PIRA - GlobeNewsWire
- 3 months ago - Tiziana Life Sciences announces publication of intranasal foralumab results - TheFly
- 3 months ago - Tiziana Life Sciences Announces the Peer-Reviewed Publication of Clinical Study Results for Intranasal Foralumab - GlobeNewsWire